Greg Martini - Ironwood Pharmaceuticals Vice Relations
| IRWD Stock | USD 3.34 0.18 5.11% |
Executive
Greg Martini is Vice Relations of Ironwood Pharmaceuticals
| Address | 100 Summer Street, Boston, MA, United States, 02110 |
| Phone | 617 621 7722 |
| Web | https://www.ironwoodpharma.com |
Ironwood Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1305 % which means that it generated a profit of $0.1305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Samuel Parisi | Alkermes Plc | 49 | |
| Blair Jackson | Alkermes Plc | 51 | |
| Jeff Christensen | Assertio Therapeutics | N/A | |
| Iain Brown | Alkermes Plc | 55 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Jerad Seurer | Avadel Pharmaceuticals PLC | 51 | |
| Sam Schlessinger | Assertio Therapeutics | 42 | |
| Peter Norman | Alkermes Plc | N/A | |
| Declan OConnor | Alkermes Plc | N/A | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Mark Elrod | Avadel Pharmaceuticals PLC | N/A | |
| Lauren Riker | Pacira BioSciences, | 45 | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| MP MBA | Amphastar P | N/A | |
| Esq III | Pacira BioSciences, | 50 | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Matthew CPA | Neurocrine Biosciences | 44 | |
| Darin Esq | Neurocrine Biosciences | 58 | |
| Tiffany MBA | Esperion Therapeutics | N/A | |
Management Performance
| Return On Equity | -5.75 | ||||
| Return On Asset | 0.13 |
Ironwood Pharmaceuticals Leadership Team
Elected by the shareholders, the Ironwood Pharmaceuticals' board of directors comprises two types of representatives: Ironwood Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ironwood. The board's role is to monitor Ironwood Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ironwood Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ironwood Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie McHugh, Independent Director | ||
| Jana Noeldeke, Basel Leader | ||
| Ronald Silver, Corporate Officer | ||
| Thomas McCourt, Chief Commercial Officer and Sr. VP of Marketing and Sales | ||
| Marcel Moulaison, Vice Operations | ||
| Beth Calitri, Head Relations | ||
| Sravan Emany, Principal VP | ||
| Jason Rickard, VP COO | ||
| Matt Roache, Director Relations | ||
| Mike Nanfito, Vice Excellence | ||
| John Minardo, Chief VP | ||
| Michael MD, Senior Officer | ||
| Greg Martini, Vice Relations | ||
| Andrew Davis, Senior Officer | ||
| MPH MD, VP Development | ||
| MBA MS, VP Operations |
Ironwood Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ironwood Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.75 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 160.03 M | ||||
| Shares Owned By Insiders | 1.68 % | ||||
| Shares Owned By Institutions | 98.32 % | ||||
| Number Of Shares Shorted | 10.96 M | ||||
| Price To Earning | 18.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.